Clinical trial
Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's…
NCT00470275 · Children's Oncology Group, Other · Completed
Key facts
| NCT number | NCT00470275 |
|---|---|
| Title | Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma |
| Official title | Phase II Trial of Intermediate-Dose Cytarabine to Modulate EWS/FLI for Children and Young Adults With Recurrent or Refractory Ewing Sarcoma |
| Lead sponsor | Children's Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Drug |
| Interventions | cytarabine |
| Enrollment | 10 |
| Start date | May 1, 2007 |
| Primary completion | Aug 1, 2008 |
| Completion | Dec 1, 2013 |
| First posted | May 7, 2007 |
| Last update posted | Oct 20, 2014 |
| Countries | Australia, Canada, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: